Literature DB >> 6277009

[Spiramycin ; therapeutic value in humans. (author's transl)].

S Kernbaum.   

Abstract

Spiramycin gives high tissue levels and has very-few side-effects. It is one of the best antibiotics in infections of the upper and lower respiratory tract and of the oral cavity. It is probably one of the most effective antibiotics against chlamydia. Spiramycin is useful when toxoplasmosis occurs during pregnancy or results in severe diseases in non-immunodepressed patients. For the reasons listed above, we believe that spiramycin has been underestimated. This is the result of assessing its value according to its rather high MIC rather than to it's effectiveness against infection in animals and humans.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6277009

Source DB:  PubMed          Journal:  Sem Hop


  9 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 2.  Pharmacodynamics and pharmacokinetics of spiramycin and their clinical significance.

Authors:  I Brook
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

Review 3.  Bacterial synergy in pelvic inflammatory disease.

Authors:  I Brook
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

4.  Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.

Authors:  S Chamberland; H A Kirst; W L Current
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

5.  Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture.

Authors:  F Derouin; C Chastang
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

6.  Pharmacokinetics of spiramycin in the rhesus monkey: transplacental passage and distribution in tissue in the fetus.

Authors:  E Schoondermark-Van de Ven; J Galama; W Camps; T Vree; F Russel; J Meuwissen; W Melchers
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

7.  Efficacy of spiramycin as an alternative to amoxicillin in the treatment of acute upper respiratory tract infections.

Authors:  C Bunnag; P Jareoncharsri; S Voraprayoon; A Vitavasiri; P Supatchaipisit; S Kongpatanakul
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

8.  In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.

Authors:  H R Chang; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

9.  Indirect enzyme-linked immunosorbent assay for immunoglobulin G and four immunoassays for immunoglobulin M to Toxoplasma gondii in a series of heart transplant recipients.

Authors:  J F Sluiters; A H Balk; C E Essed; B Mochtar; W Weimar; M L Simoons; E P Ijzerman
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.